Cambridge Antibody Technology and Dyax Corp. announced a further amendment to their existing licensing agreement. The new agreement extends the arrangement that was previously announced in January 2003 and grants Dyax, amongst other benefits, an increased number of options for licences to develop therapeutic and diagnostic antibody products under CAT's patents for Dyax's own use and on behalf of its partners.

CAT and Dyax have further agreed that, as a result of this agreement, royalties will not be due to Dyax in respect of Humira.

Peter Chambre, CAT's Chief Executive Officer, commented: "We are delighted to have expanded our agreement with Dyax and to have resolved the position with respect to Humira."

Henry E. Blair, Dyax's Chairman, President and Chief Executive Officer, commented "We are very pleased to expand further our licensing arrangement with CAT. This expansion significantly increases the potential number of antibody products Dyax can discover both for our own pipeline and for collaborators."